4.84
-0.16(-3.20%)
Currency In USD
| Previous Close | 5 |
| Open | 4.9 |
| Day High | 5.09 |
| Day Low | 4.78 |
| 52-Week High | 12.36 |
| 52-Week Low | 3.79 |
| Volume | 21.28M |
| Average Volume | 23.39M |
| Market Cap | 1.93B |
| PE | -2.69 |
| EPS | -1.8 |
| Moving Average 50 Days | 4.89 |
| Moving Average 200 Days | 6.39 |
| Change | -0.16 |
If you invested $1000 in Recursion Pharmaceuticals, Inc. (RXRX) since IPO date, it would be worth $154.63 as of June 18, 2025 at a share price of $4.84. Whereas If you bought $1000 worth of Recursion Pharmaceuticals, Inc. (RXRX) shares 3 years ago, it would be worth $577.57 as of June 18, 2025 at a share price of $4.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
GlobeNewswire Inc.
Jun 06, 2025 2:00 PM GMT
Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at speeds up to 1000x faster in standard benchmarks
Recursion to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Ban
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
GlobeNewswire Inc.
May 04, 2025 4:45 PM GMT
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82